Merck adds Lilly neuroscience veteran
Lilly's global head of neuroscience research and early clinical investigation Darryle Schoepp jumps to Merck where he will serve as senior VP and franchise head of neuroscience, the company says March 5. In that role he will oversee drug discovery and development and report to Merck Research Laboratories President Peter Kim. The most advanced neuroscience product in Merck's pipeline is the Phase III insomnia agent gaboxadol...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”